Frailty and the Need for Better Support
Frailty is a condition that can develop as people age and become more vulnerable to physical stress. It is often linked with reduced strength, slower walking speed, fatigue, lower activity levels, and decreased resilience.
For many older adults, frailty can make everyday tasks more difficult. Walking, standing, exercising, climbing stairs, or recovering from illness may become more challenging. Because frailty can affect independence and quality of life, researchers are studying new ways to support strength, mobility, and healthy aging.
Current approaches often include exercise, nutrition, supplements, and management of underlying health conditions. These remain important, but regenerative medicine is also being explored as a way to support the biological factors involved in age-related physical decline.
Why UC-MSCs Are Being Studied
Umbilical cord-derived mesenchymal stem cells, or UC-MSCs, are being studied in regenerative medicine because they release signaling molecules that may influence inflammation, immune balance, tissue repair, and cellular communication.
Frailty is not caused by one single issue. It may involve chronic low-grade inflammation, reduced muscle function, lower physical reserve, changes in immune activity, and age-related cellular stress. Because UC-MSCs may help regulate inflammation and support repair-related signaling, researchers are interested in whether they may help improve physical function in older adults with frailty.
Rather than acting as replacement cells, MSCs are often studied for their paracrine effects, meaning the helpful signals they release into the surrounding environment.
Inside the Phase 2 Trial
This phase 2 clinical trial was conducted at Vinmec Times City International General Hospital between 2021 and 2024. The study included 147 frail adults between the ages of 60 and 85.
Participants were randomly assigned to one of two groups:
- A UC-MSC group receiving two intravenous UC-MSC infusions plus oral supplements
- A control group receiving oral supplements alone
The UC-MSC group received 1.5 × 10⁶ cells per kilogram of body weight, with two infusions given three months apart. All participants were followed for 9 months.
Researchers evaluated safety and several measures of physical function and quality of life, including:
- Short Physical Performance Battery, or SPPB
- Walking speed
- Handgrip strength
- Physical activity levels
- Fatigue
- Knee function
- General health status
- Inflammatory and aging-related biomarkers
What Researchers Observed
The study reported encouraging results for both safety and physical performance.
No UC-MSC therapy-related serious adverse events occurred during the study and the reported treatment-related adverse events were mild, including symptoms such as headache, dizziness, and chest discomfort, and they resolved on their own.
The UC-MSC group also showed stronger improvements in physical performance compared with the control group. One of the main measures was the Short Physical Performance Battery, which evaluates balance, walking speed, and chair-stand ability. Higher SPPB scores reflect better lower-body physical function.
At 9 months, the UC-MSC group had higher SPPB scores than the control group. The researchers also observed meaningful improvements in areas such as gait speed, handgrip strength, physical activity, fatigue, knee-related symptoms, and general health status.
These findings suggest that UC-MSC infusion may help support several important parts of physical function that matter in everyday aging.
The Biology Behind the Results
A key reason UC-MSCs are being studied for frailty is their ability to influence inflammation and immune signaling. Aging is often associated with a gradual increase in inflammatory activity, sometimes called “inflammaging.” This low-grade inflammation may contribute to fatigue, muscle weakness, reduced mobility, and slower recovery.
UC-MSCs may help support the body by releasing biological signals that encourage a more balanced inflammatory response. These signals may also influence tissue repair, mitochondrial function, immune cell activity, and cellular aging pathways.
The study also included biomarker analysis, which gave researchers a closer look at possible biological changes after UC-MSC infusion. The authors noted favorable changes in inflammatory and senescence-related biomarkers, supporting the idea that UC-MSCs may affect both functional outcomes and the underlying biological environment.
In simpler terms, the therapy may help support the body’s repair and communication systems in ways that are relevant to aging and physical resilience.
Why This Study Matters
This study is important because it builds on earlier frailty research with a larger group of participants and a longer follow-up period. Frailty research is especially meaningful because even modest improvements in strength, walking ability, fatigue, or physical activity can make a noticeable difference in daily life.
For regenerative medicine, the findings support continued interest in UC-MSCs as a potential approach for age-related functional decline. The study suggests that UC-MSC infusion may be associated with improved physical performance and quality-of-life measures while maintaining a favorable safety profile in this clinical setting.
It also adds to the broader understanding of how regenerative therapies may support healthy aging by targeting inflammation, immune balance, and cellular repair signaling.
Looking Forward
The findings from this phase 2 trial provide a strong foundation for future research. Larger, double-blind, multicenter phase 3 trials can help confirm the results, refine dosing schedules, and better understand how long the benefits may last.
Future studies may also help identify which patients are most likely to respond and how UC-MSC therapy could fit alongside exercise, nutrition, and other healthy aging strategies.
As the field continues to grow, UC-MSC research may help shape new approaches focused on strength, mobility, resilience, and better quality of life in aging adults.
Takeaway
This phase 2 clinical trial provides encouraging evidence that allogeneic umbilical cord-derived MSC infusion may support physical function in older adults with frailty. Participants who received UC-MSC therapy showed improvements in mobility-related measures, strength, activity, fatigue, knee symptoms, and general health status compared with controls.
While continued research is needed, the study highlights the potential of UC-MSCs as a regenerative medicine approach focused on healthy aging, inflammation balance, and improved physical resilience.
Source
Nguyen LT, Nguyen KT, Dao LTM, Hoang VT, Phan TTK, Dinh NTH, Nguyen HT, Nguyen ATP, Nguyen TTN, Ho TTK, Nguyen QM. Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial. eBioMedicine. 2026 May;127:106268. doi: 10.1016/j.ebiom.2026.106268. PMID: 42019090; PMCID: PMC13123506. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC13123506/
Related Treatment Pages